ClinicalTrials.gg
RecruitingNCT06591247StrippingUpdated Apr 15, 2026

Membrane Stripping for Cervical Ripening

An interventional study of Double Baloon Catheter and Membrane Stripping in Labor, Induced, Cervical Ripening and Balloon Induction, sponsored by Meir Medical Center. Recruiting at 1 site in Israel. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Meir Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

The goal of this interventional study is to evaluate the effectiveness of membrane stripping in cervical ripening compared to double balloon catheter induction.

The study population consists of women undergoing labor induction.

The main questions it aims to answer are:

  1. Is membrane stripping as effective as double balloon catheter induction in cervical ripening?
  2. What is the influence of membrane stripping on the time required for cervical ripening, delivery duration, and maternal and fetal outcomes compared to balloon induction.
02

Conditions studied

  • Labor, Induced
  • Cervical Ripening
  • Balloon Induction
  • Membrane Stripping
  • Pregnancy Related
  • Induction of Birth
03

In context

Lead sponsor

Meir Medical Center is the lead sponsor of 402 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 and above
  • Patients with a cervical dilation of at least 1 cm
  • Full-term pregnancy
  • Cephalic presentation
  • No to vaginal delivery

Exclusion criteria

Exclusion Criteria:

  • Patients with rupture of membranes
  • Patients who do not require cervical ripening and proceed directly to the delivery room for induction with oxytocin
  • Patients for whom the use of a double-balloon catheter/PGE2 is
  • Twin pregnancies
  • Pregnancies with macrosomic fetuses where vaginal delivery is contraindicated
  • Patients with maternal or fetal pathologies that do not allow for vaginal delivery due to concerns about fetal or maternal distress
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Active comparator
    Double Balloon Catheter induction

    A Double balloon catheter will be inserted for 12 hours in this group of women

    Device: Double Baloon Catheter

  • Active comparator
    Membrane stripping

    This group of women will undergo membrane stripping twice (every 4-6 hours) over a period of 12 hours

    Procedure: Membrane Stripping

  • Active comparator
    PGE2 induction

    This group of women will undergo cervical ripening using a vaginal PGE2 pessary

    Drug: PGE2

Interventions

  • DeviceDouble Baloon Catheter

    A double Baloon Catheter will be inserted for 12 hours to one of the arms of the study

  • ProcedureMembrane Stripping

    Stripping will be considered as 3-5 rotations of separating the amniotic sac from the cervix and will be perfomed twice (every 4-6 hours)

  • DrugDinoprostoneStudies of DinoprostoneDinoprostone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A PGE2 vaginal pessary (Cervidil) will be inserted for 12-24 hours

06

What researchers measure

Primary outcomes

  1. Rates of successful cervical ripening at the end of 12 hours, duration of cervical ripening

    What percentage of the women in this arm had a successful cervical ripening after 12 hours

    Time frame: from 12 hours after intervention until patient&s discharge or 150 hours, whichever came first, assessed up to 100 months

Secondary outcomes

  1. Rates of vaginal delivery within 24 hours

    What percentage of the women in this arm delivered within 24 hours

    Time frame: from 12 hours after intervention until patients discharge or 150 hours, whichever came first, assessed up to 100 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2024 (actual). Primary completion is estimated for Dec 2027, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2024
First posted
Sep 19, 2024
StartActual
Aug 7, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06591247
Responsible party
Gal Cohen (Gal Cohen MD, Principal Investigator, Meir Medical Center) — Principal investigator
First posted
Sep 19, 2024
Start date
Aug 7, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 15, 2026

Study contacts

Gal Cohen, MD
Contact
galcwork@gmail.com
+972545915788

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dinoprostone

Start the discussion